AXL targeting restores PD-1 blockade sensitivity of
AMP-Activated Protein Kinase Kinases
Animals
CD8-Positive T-Lymphocytes
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Humans
Lung Neoplasms
/ drug therapy
Mice
Programmed Cell Death 1 Receptor
/ genetics
Protein Serine-Threonine Kinases
/ genetics
Proto-Oncogene Proteins
/ metabolism
Receptor Protein-Tyrosine Kinases
/ metabolism
Axl Receptor Tyrosine Kinase
Axl
NSCLC
STK11/LKB1 mutation
TCF1 CD8 T cells
immunotherapy
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
10
05
2021
revised:
22
10
2021
accepted:
08
02
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Mutations in
Identifiants
pubmed: 35492873
doi: 10.1016/j.xcrm.2022.100554
pii: S2666-3791(22)00060-X
pmc: PMC9040166
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Proto-Oncogene Proteins
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
STK11 protein, human
EC 2.7.11.1
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Axl Receptor Tyrosine Kinase
0
Banques de données
ClinicalTrials.gov
['NCT03184571']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
100554Subventions
Organisme : NCI NIH HHS
ID : U54 CA224065
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210181
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA243577
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
This work was supported in part by a sponsored research agreement from BerGenBio ASA to R.A.B. A.R., D.M., H.G., and G.G. are current employees of BerGenBio ASA and J.B.L. is a former employee of BerGenBio ASA. M.C. is a current employee of Merck &Co., Inc., Kenilworth, NJ. J.D.M. receives licensing royalties from the NIH and UTSW for distribution of human tumor lines. H.L., Z.L., D.M., J.B.L., J.D.M., and R.A.B. are authors of a patent related to this study. The remaining authors have no competing interests.
Références
Immunity. 2019 Nov 19;51(5):840-855.e5
pubmed: 31606264
J Thorac Oncol. 2022 Mar;17(3):399-410
pubmed: 34740862
Br J Cancer. 2017 Feb 14;116(4):415-423
pubmed: 28072762
Nat Microbiol. 2018 Mar;3(3):302-309
pubmed: 29379210
Cancer Res. 2018 Jan 1;78(1):246-255
pubmed: 29180468
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
PLoS One. 2020 Sep 3;15(9):e0238358
pubmed: 32881920
Elife. 2016 Jun 28;5:
pubmed: 27350258
J Immunol. 2019 Jan 1;202(1):292-299
pubmed: 30510069
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
J Thorac Oncol. 2019 Jun;14(6):1095-1101
pubmed: 30738221
Genome Biol. 2017 Jul 5;18(1):127
pubmed: 28679386
Leukemia. 2010 Oct;24(10):1785-8
pubmed: 20686503
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
J Exp Med. 2010 Apr 12;207(4):823-36
pubmed: 20351058
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Cancer Cell. 2014 Jan 13;25(1):37-48
pubmed: 24434209
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Nature. 2020 Jul;583(7817):609-614
pubmed: 32581358
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Ann Oncol. 2017 Jan 1;28(1):75-82
pubmed: 27687306
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
J Thorac Oncol. 2020 Jun;15(6):973-999
pubmed: 32018052
Clin Cancer Res. 2020 Feb 1;26(3):679-689
pubmed: 31645352
J Immunol. 2007 May 1;178(9):5635-42
pubmed: 17442946
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Cell. 2020 Sep 14;38(3):400-411.e6
pubmed: 32619407
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Nat Rev Cancer. 2009 Aug;9(8):563-75
pubmed: 19629071
Oncotarget. 2017 Sep 21;8(52):89761-89774
pubmed: 29163786
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Nat Immunol. 2014 Oct;15(10):920-8
pubmed: 25194421
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Trends Immunol. 2013 Feb;34(2):67-73
pubmed: 23122052
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Nat Immunol. 2020 May;21(5):546-554
pubmed: 32231300
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Mol Cancer. 2019 Feb 11;18(1):24
pubmed: 30744655
J Immunol. 2009 Sep 1;183(5):3004-13
pubmed: 19657094
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Sci Transl Med. 2020 Jun 24;12(549):
pubmed: 32581136
Curr Biol. 2003 Nov 11;13(22):2004-8
pubmed: 14614828
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Nature. 1995 Feb 16;373(6515):623-6
pubmed: 7854420
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
Br J Cancer. 2008 Jul 22;99(2):245-52
pubmed: 18594528
Cancer Discov. 2019 Nov;9(11):1606-1627
pubmed: 31350328
Cell. 2020 Aug 6;182(3):655-671.e22
pubmed: 32603654
Clin Cancer Res. 2017 Jan 1;23(1):193-203
pubmed: 27354469
Oncotarget. 2017 Jul 18;8(29):48248-48252
pubmed: 28525386
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Nat Commun. 2016 Dec 23;7:13898
pubmed: 28008921
Nat Protoc. 2008;3(12):1932-40
pubmed: 19180077